MPS Ltd Delivers Record Q1 FY27 Results

MPS Ltd reported a record first quarter for FY27, with revenue climbing 20.4% year-over-year to ₹224.24 crore and EBITDA jumping 53.0% to ₹76.96 crore.

Reader Takeaway: Strong revenue growth and margin expansion driven by strategic shift; acquisition integration positive.

What Just Happened

MPS Ltd announced its Q1 FY27 financial results, showcasing significant year-over-year growth. Revenue stood at ₹224.24 crore, a 20.4% increase, while EBITDA reached ₹76.96 crore, up 53.0%. The company also reported a Profit After Tax of ₹50.39 crore, a 43.0% rise, and an all-time Q1 high for Basic EPS of ₹29.70.

EBITDA margins expanded to 34.3%, reflecting improved operational efficiency and a changing revenue mix.

Why This Matters

The strong performance indicates that MPS Ltd's strategic pivot towards outcomes-based revenue models, such as manuscript acceptance and integrity checks, is succeeding. This shift is driving margin expansion, as seen in the EBITDA margin reaching 34.3%, comfortably meeting the company's "Rule of 50" KPI (sum of revenue growth and EBITDA margin).

The Backstory

MPS Ltd has been focusing on evolving its business model from effort-based services to outcome-based solutions. This includes integrating recent acquisitions like Unbound Medicine, which is contributing recurring revenue and offers cross-selling opportunities.

The company's balance sheet remains healthy, with cash and cash equivalents at ₹138.02 crore and total borrowings at ₹37.63 crore as of June 30, 2026.

What Changes Now

With a strong Q1 performance, MPS Ltd has reaffirmed its FY27 EBITDA expectation to exceed ₹300 crore. For FY28, the company targets approximately ₹1,500 crore in revenue and ₹450 crore in EBITDA.

Management is also selectively pruning its client base, particularly in the Author Solutions business, to focus on more profitable engagements.

Risks to Watch

While the results are strong, investors will monitor the successful integration of Unbound Medicine and the realization of synergies. Continued acceleration in organic growth and the ability to maintain margin expansion in a competitive landscape are key.

Peer Comparison

(No specific peer comparison data available in the filing.)

Context Metrics

• Revenue Solutions: Contributed ₹123.23 crore (13.2% YoY growth), EBITDA grew 37.9%.
• Education Solutions: Saw a significant 42.2% YoY revenue growth, reaching ₹73.41 crore.
• Corporate Learning: Grew 6.9% to ₹27.60 crore, with EBITDA margins improving to 25.3%.

Unbound Medicine, acquired recently, is operating at a monthly run rate of approximately USD 800,000 with 18-20% margins, expected to increase.

What to Track Next

Investors will be closely watching MPS Ltd's progress in the upcoming quarters, focusing on sustained revenue growth, further margin improvements, and the successful execution of its strategic goals, including synergies from acquisitions.